Wellhausen and colleagues [108] focused on developing a universal CAR-T cell therapy and base-edited CD45, a pan-leukocyte antigen, in hematopoietic stem cells, so that the CAR-T cells could target CD45 on the cancer cells, but the engrafted hematopoietic stem cells and the CAR-T cells would not be killed. Here, PTPRC is linked to cancer.